Berlin, Germany
Provolut, founded in 2022 and headquartered in Germany, is at the forefront of transforming protein design using artificial intelligence (AI) and machine learning (ML). Their mission is to empower biotech innovators by streamlining protein engineering campaigns to unlock breakthrough possibilities in healthcare, sustainability, and industrial transformation.
Provolut's proprietary platform, Exazyme, leverages cutting-edge AI and bioinformatics to design superior proteins, reducing experimental efforts by up to 100x compared to traditional methods. This approach minimizes data requirements and explores vast sequence spaces, drastically accelerating timelines and achieving superior outcomes.
Key backing from renowned investors such as AIX Ventures and Atlantic Labs, alongside co-financing from the IBB ProFIT program and the European Union’s EFRE program, underscores confidence in Provolut's vision. The company secured a €2.00M Seed Round investment on 15 May 2023, affirming its promising avenue in the Biotechnology and Pharmaceutical industries.
